W81XWH-21-BCRP-TBCCA-2: DoD Breast Cancer, Transformative Breast Cancer Research Award
Closed
This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.
Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $38.8 million in total. Applications closed on October 5, 2021.
From the official notice on Grants.gov, last changed April 26, 2021. Checked November 7, 2026.
- Total funding$38.8 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement, Grant
Key dates
| Posted | April 26, 2021 |
|---|---|
| Deadline | October 5, 2021 |
| Archived by Grants.gov | November 4, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (59% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system. The consortium should have at least four, but no more than five, teams investigating different projects under a central hypothesis. No more than two teams may be based at one institution. Each team’s work must be integrated within the consortium so that every component is working toward the consortium’s central hypothesis. Note: This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects. The proposed consortium’s overall work is expected to be innovative. In addition, the Transformative Breast Cancer Consortium Award will include funds for “seed projects” to pursue brand new, high-risk/high-reward concepts that arise from the work, during the award period. If the work proposed meets the criteria or scope of one of the FY21 BCRP Breakthrough Awards (see W81XWH-21-BCRP-BTA12-2 for Levels 1 and 2, W81XWH-21-BCRP-BTA3-2 for Level 3, and W81XWH-21-BCRP-BTA4-2 for Level 4), it is not appropriate for the Transformative Breast Cancer Consortium Award mechanism. The Breast Cancer Landscape describes the reality of breast cancer and identifies overarching challenges to progress the field. Research funded under this award mechanism should result in answers ransform and disrupt the present landscape. Applications submitted to the Transformative Breast Cancer Consortium Award must include the following: · Research that includes truly innovative and brand-new paradigm shifting work in breast cancer that will address vital issues in a unique way.
Who has won Military Medical Research and Development grants before
From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 81 | $546 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 139 | $166 million |
| The Johns Hopkins University | Maryland | 157 | $153 million |
| The Regents of the University of California, San Francisco | California | 113 | $147 million |
| Duke University | North Carolina | 86 | $123 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is W81XWH-21-BCRP-TBCCA-2 still open?
No. It closed on October 5, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).
Who can apply for DoD Breast Cancer, Transformative Breast Cancer Research Award?
Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.
What is the deadline for DoD Breast Cancer, Transformative Breast Cancer Research Award?
Closed October 5, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $38.8 million in total for one award.
Who has won Military Medical Research and Development grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.